DEXCOM INC
DXCMHealthcaredexcom.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 29, 2026
Next reportFebruary 10, 2027after close · forecast 0.736 $/share
Revenue
$1.34B
▲ +11.2% vs prior year YoY
Net income
$275.10M
▼ -3.1% vs prior year YoY
EPS
0.72$
▲ +2.9% vs prior year YoY
Net margin
20.5%
▼ -3.0 pp vs prior year YoY
Revenue▲ +11.2%
Margins (% of revenue)GrossOperatingNet
Net income▼ -3.1%
EPS▲ +2.9%
Financial statements
View 10-Q filed October 29, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.19B | $1.31B | $1.34B | ▲ +11.2% |
| Gross profit | $655.80M | $589.00M | $688.80M | $731.40M | $792.70M | $750.30M | $830.00M | $864.40M | ▲ +18.2% |
| Operating income | $188.90M | $133.70M | $212.60M | $242.50M | $323.00M | $255.30M | $318.30M | $327.20M | ▲ +34.9% |
| Net income | $151.70M | $105.40M | $179.80M | $283.80M | $267.30M | $199.50M | $249.10M | $275.10M | ▼ -3.1% |
| R&D | $139.50M | $145.20M | $148.20M | $157.50M | $148.20M | $145.30M | $153.00M | $161.60M | ▲ +2.6% |
| EPS (diluted) | — | 0.27 $ | 0.45 $ | 0.70 $ | — | 0.51 $ | 0.64 $ | 0.72 $ | ▲ +2.9% |
| Margins (% of revenue) | |||||||||
| Gross | 58.9 % | 56.9 % | 59.5 % | 60.5 % | 62.9 % | 62.9 % | 63.4 % | 64.3 % | ▲ +3.8 pt |
| Operating | 17.0 % | 12.9 % | 18.4 % | 20.1 % | 25.6 % | 21.4 % | 24.3 % | 24.3 % | ▲ +4.3 pt |
| Net | 13.6 % | 10.2 % | 15.5 % | 23.5 % | 21.2 % | 16.7 % | 19.0 % | 20.5 % | ▼ -3.0 pt |
| Balance sheet | |||||||||
| Assets | $6.48B | $6.75B | $7.33B | $7.50B | $6.34B | $6.63B | $6.46B | $6.24B | ▼ -16.8% |
| Liabilities | $4.38B | $4.49B | $4.75B | $4.77B | $3.59B | $3.68B | $3.83B | $3.70B | ▼ -22.4% |
| Equity | $2.10B | $2.27B | $2.57B | $2.73B | $2.75B | $2.96B | $2.62B | $2.54B | ▼ -7.0% |
| Cash | $606.10M | $904.90M | $1.16B | $1.84B | $917.70M | $1.12B | $1.10B | $961.40M | ▼ -47.6% |
| Capital | |||||||||
| Shares outstanding | 390.77M | 392.11M | 392.16M | 390.02M | 384.86M | 385.87M | 377.36M | 372.95M | ▼ -4.4% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.